BeOne Medicines

BeiGene, Ltd. is a global biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines for cancer patients worldwide. Founded in 2010 and headquartered in Cambridge, Massachusetts, USA, with major operational and research centers in Beijing, China, the company has rapidly grown into one of the world’s leading oncology-focused biotechnology organizations. BeOne Medicines combines advanced cancer biology, immunology, medicinal chemistry, and precision medicine to develop next-generation targeted therapies and immuno-oncology treatments.

The company’s research portfolio includes therapies for hematologic malignancies, solid tumors, and immune-related diseases, supported by an extensive pipeline of clinical-stage drug candidates. BeiGene operates one of the largest global oncology clinical development programs, with research collaborations spanning North America, Europe, Asia-Pacific, and Latin America. Its integrated capabilities include drug discovery, clinical research, manufacturing, regulatory affairs, and worldwide commercialization.

BeiGene has invested heavily in state-of-the-art manufacturing facilities and scientific infrastructure to support the global supply of innovative oncology medicines. The company emphasizes high-quality manufacturing, regulatory compliance, sustainability, and patient-centered healthcare innovation. Through continuous research and international collaboration, BeiGene aims to improve access to advanced cancer therapies while advancing the future of precision oncology and biotechnology on a global scale.